A new flow-cytometry-based opsonophagocytosis assay for the rapid measurement of functional antibody levels against Group B Streptococcus.

[1]  P. Heath.  An update on vaccination against group B streptococcus , 2011, Expert review of vaccines.

[2]  M. M. Ho,et al.  Immunogenicity and physico-chemical characterisation of a candidate conjugate vaccine against group B streptococcus serotypes Ia, Ib and III. , 2011, Vaccine.

[3]  E. Simons.  Measurement of Phagocytosis and of the Phagosomal Environment in Polymorphonuclear Phagocytes by Flow Cytometry , 2010, Current protocols in cytometry.

[4]  L. Paoletti,et al.  A fluorescence-based opsonophagocytosis assay to measure the functional activity of antibody to group B Streptococcus , 2009, Human vaccines.

[5]  L. Paoletti,et al.  Functional activity of antisera to group B streptococcal conjugate vaccines measured with an opsonophagocytosis assay and HL-60 effector cells , 2008, Human vaccines.

[6]  W. Schaffner,et al.  Epidemiology of invasive group B streptococcal disease in the United States, 1999-2005. , 2008, JAMA.

[7]  S. Grinstein,et al.  Regulation of Vacuolar pH and Its Modulation by Some Microbial Species , 2007, Microbiology and Molecular Biology Reviews.

[8]  L. Paoletti,et al.  Dose-response to type V group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine in healthy adults. , 2007, Vaccine.

[9]  S. Schrag,et al.  The prevention of neonatal group B streptococcal disease: a report by a working group of the Medical Screening Society , 2005, Journal of medical screening.

[10]  J. Cardelli,et al.  Opsonized Virulent Brucella abortus Replicates within Nonacidic, Endoplasmic Reticulum-Negative, LAMP-1-Positive Phagosomes in Human Monocytes , 2005, Infection and Immunity.

[11]  A. Schuchat,et al.  Perinatal infections due to group B streptococci. , 2004, Obstetrics and gynecology.

[12]  C. Baker,et al.  Immunization of pregnant women with group B streptococcal type III capsular polysaccharide-tetanus toxoid conjugate vaccine. , 2003, Vaccine.

[13]  D. Kasper,et al.  Safety and immunogenicity of a bivalent group B streptococcal conjugate vaccine for serotypes II and III. , 2003, The Journal of infectious diseases.

[14]  A. Schuchat,et al.  Effects of intrapartum antimicrobial prophylaxis for prevention of group-B-streptococcal disease on the incidence and ecology of early-onset neonatal sepsis. , 2003, The Lancet. Infectious diseases.

[15]  J. Plested,et al.  Opsonophagocytosis assay using flow-cytometry. , 2003, Methods in molecular medicine.

[16]  M. Hornef,et al.  Bacterial strategies for overcoming host innate and adaptive immune responses , 2002, Nature Immunology.

[17]  D. Kasper,et al.  Induction of cross-reactive antibodies by immunization of healthy adults with types Ia and Ib group B streptococcal polysaccharide-tetanus toxoid conjugate vaccines. , 2002, The Journal of infectious diseases.

[18]  J. V. D. van de Winkel,et al.  Flow cytometry-based phagocytosis assay for sensitive detection of opsonic activity of pneumococcal capsular polysaccharide antibodies in human sera. , 2001, Journal of immunological methods.

[19]  A. Podda.  The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. , 2001, Vaccine.

[20]  D. Kasper,et al.  Use of capsular polysaccharide-tetanus toxoid conjugate vaccine for type II group B Streptococcus in healthy women. , 2000, The Journal of infectious diseases.

[21]  A. Schuchat.  Neonatal group B streptococcal disease--screening and prevention. , 2000, The New England journal of medicine.

[22]  D. Kasper,et al.  Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib. , 1999, The Journal of infectious diseases.

[23]  J. Whitin,et al.  Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells , 1997, Clinical and diagnostic laboratory immunology.

[24]  D. Kasper,et al.  Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine. , 1996, The Journal of clinical investigation.

[25]  T. Miyoshi,et al.  Neonatal Group B Streptococcal Sepsis During 2 Years of a Universal Screening Program , 1994, Obstetrics and gynecology.

[26]  M. Wessels,et al.  Identification of a genetic locus essential for capsule sialylation in type III group B streptococci , 1992, Infection and immunity.

[27]  P. Ferrieri.  GBS infections in the newborn infant: diagnosis and treatment. , 1985, Antibiotics and chemotherapy.

[28]  K. Boyer,et al.  Selective intrapartum chemoprophylaxis of neonatal group B streptococcal early-onset disease. I. Epidemiologic rationale. , 1983, The Journal of infectious diseases.

[29]  K. Boyer,et al.  Selective intrapartum chemoprophylaxis of neonatal group B streptococcal early-onset disease. II. Predictive value of prenatal cultures. , 1983, The Journal of infectious diseases.

[30]  D. Kasper,et al.  Antibody-independent classical pathway-mediated opsonophagocytosis of type Ia, group B streptococcus. , 1982, The Journal of clinical investigation.

[31]  D. Kasper,et al.  Antibody to group B Streptococcus type III in human sera measured by a mouse protection test , 1981, Infection and immunity.

[32]  D. Kasper,et al.  Opsonic specificity of human antibody to the type III polysaccharide of group B Streptococcus. , 1979, The Journal of infectious diseases.

[33]  D. Kasper,et al.  Antigenic specificity of opsonophagocytic antibodies in rabbit anti-sera to group B streptococci. , 1977, Journal of immunology.

[34]  G. Mccracken.  Group B streptococci: the new challenge in neonatal infections. , 1973, The Journal of pediatrics.